Resultaterne fra disse analyser førte derefter til en afblinding i begge studier for at gøre det muligt for patienter i placebo/ dexamethason- gruppen at modtage behandling med lenalidomid/ dexamethason- kombinationen.
Results of these analyses subsequently led to an unblinding in both studies, in order to allow patients in the placebo/dexamethasone group to receive treatment with the lenalidomide/dexamethasone combination.